BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » insurance

Cord Blood Industry Survival May Depend on Mass Affordability of Treatments Through Specialized Insurance Coverage

February 8, 2018 By Cade Hildreth (CEO) Leave a Comment

Smart Stem Plus, Cord Blood Insurance Co.

[Alexandra Romero, Guest Author]  Recently, I had the opportunity to attend one of the largest events related to the Stem Cell and Regenerative Medicine Industry – Phacilitate/World Stem Cell Summit 2018. During the Plenary Super Session, Co-Chair Anthony Davies heavily discussed on a series of “fireside chats” the extremely high cost of some of the new stem cell-based treatments that have been recently approved. These conversations set the tone for one of the most discussed topics throughout  the conference that gathered a great number of leaders not only from the medical and research fields, but also from the business sector. The “elephant in the room” seemed to finally be acknowledged, at least to some extent.

On the other hand, at the Cord Blood and Perinatal Stem Cells sessions, the big question on everybody’s mind was whether there is anything remarkably new and promising in the horizon that will allow the industry to stop its slow but steady decline caused by the lack of recent advancements. It was clear to the attendees (cord blood banks, investors, and research scientists), that the market has been experiencing a slow and chronic decline over the past 5 years, and there is a serious need to offer more options in terms of innovative and accessible treatments in order for the industry to remain sustainable in upcoming years. There has been a rapid evolution in the sources to obtain and utilize stem cells, which have been thoroughly addressed by Bioinformant in previous articles.  [Read more…]

Filed Under: Cord Blood Tagged With: cord blood, insurance, Smart Stem Plus

WideCells’ CellPlan Insurance is Live – 1st Sales Made to Biovault’s Base of Cord Blood Banks

January 8, 2017 By Cade Hildreth (CEO) Leave a Comment

World first stem cell insurance plan, CellPlan, secures maiden sales agreement signaling commencement of commercial roll out.

WideCells CellPlanCellPlan Limited (‘CellPlan’), which has developed the world’s first stem cell healthcare insurance plan and medical concierge service, has cemented its agreement with Biovault Technical Ltd (‘Biovault’), the UK’s largest private human tissue storage facility via a definitive agreement. CellPlan is part of London-listedWideCells Group plc, the healthcare services company focused on providing end-to-end stem cell services. [Read more…]

Filed Under: Cord Blood, Exosomes, HSCs Tagged With: CellPlan, insurance, WideCell

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.